Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 220

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 220
---
 only two projects, therefore we accounted for expected income and expenses related to these indications alone and did not take into consideration developments that the Company might be performing in the future.

Another assumption made for the sake of the current valuation is that the Company will develop the two indications on its own until the successful termination of the Phase II clinical trials and following that will seek for a business agreement with a large pharma company that will perform the Phase III clinical trials (on its own account) and after the successful conclusion of the trials will continue and market the finished products. The Company will be entitled to an upfront payment at the end of Phase II and royalties from the third-party revenues.

As mentioned before, Telomir holds the marketing rights for North America only while the marketing rights for the rest of the world are held by another company (“NewCo”). We have performed the current valuation and NewCo’s valuation under the assumption that the developing costs will be expensed equally by both companies, even if the actual development is performed by only one of them.

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 15 of 24 |

Timeline of the development of the Indications

Based on information received from the company and our own research we have assumed the following regarding the development of the AMD and Breast cancer Indications:

The timeline is presented in the following chart:

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 16 of 24 |

Total Available Markets

The company holds the exclusive license rights in the U.S, Canada and Mexico, therefore our estimations of the potential markets are solely based on these geographical markets.

AMD

Our estimations of the AMD market size are based on the prevalence of Dry AMD (Early and Late stages) in the US population 4(Thousands).

The above figures are based on the current adult populations in each of the geographical markets. The valuation is based on estimations of the future populations in these markets, as follows (New Treatable cases):

4 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2797921#eoi220068t1

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 17 of 24 |

Breast Cancer

The estimations of the Breast Cancer population are based on the Incidence rates of Breast Cancer in the Female population of the US, Canada and Mexico, as follows:

Based on the number